Denali Therapeutics Inc.
Anti-ApoE antibodies

Last updated:

Abstract:

The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Status:
Grant
Type:

Utility

Filling date:

27 Oct 2017

Issue date:

21 Sep 2021